Caris Life Sciences, Inc. (CAI) – What Are Investment Firms Thinking About This Stock?

Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $31.18.

CAI has been the subject of a number of recent research reports. BTIG Research reissued a “buy” rating and issued a $38.00 target price on shares of Caris Life Sciences in a report on Thursday, November 5th. Citigroup upped their price target on shares of Caris Life Sciences from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, November 6th. UBS Group set a $38.00 price objective on shares of Caris Life Sciences in a research report on Thursday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Finally, TD Cowen boosted their target price on Caris Life Sciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, November 5th.

View Our Latest Research Report on CAI

Caris Life Sciences Stock Performance

CAI opened at $21.00 on Thursday. The stock has a market capitalization of $6.02 billion, a price-to-earnings ratio of 63.64, a PEG ratio of 7.81 and a beta of 0.71. The company has a fifty day moving average of $29.31 and a 200 day moving average of $21.68. Caris Life Sciences has a fifty-two week low of $14.19 and a fifty-two week high of $36.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.84 and a current ratio of 6.71.

Caris Life Sciences (NASDAQ:CAI – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.03 by $0.02. The business had revenue of $275.36 million for the quarter. Caris Life Sciences had a net margin of 9.16% and a return on equity of 16.00%. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.08 EPS. As a group, sell-side analysts forecast that Caris Life Sciences will post 0.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Caris Life Sciences news, President David Spetzler sold 478,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the completion of the sale, the president directly owned 1,052,083 shares of the company’s stock, valued at approximately $26,154,783.38. This represents a 31.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Brille sold 400,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the transaction, the insider owned 230,303 shares of the company’s stock, valued at approximately $6,985,089.99. This trade represents a 63.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,004,712 shares of company stock valued at $27,205,419 over the last 90 days. Corporate insiders own 50.00% of the company’s stock.

Institutional Trading of Caris Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. WCG Wealth Advisors LLC raised its position in shares of Caris Life Sciences by 56.8% in the 3rd quarter. WCG Wealth Advisors LLC now owns 54,475 shares of the company’s stock valued at $1,669,000 after purchasing an additional 19,739 shares during the last quarter. Worldquant Millennium Advisors LLC increased its stake in Caris Life Sciences by 273.0% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 761,420 shares of the company’s stock valued at $23,322,000 after purchasing an additional 557,268 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Caris Life Sciences by 214.6% in the third quarter. Bellevue Group AG now owns 20,191 shares of the company’s stock worth $618,000 after buying an additional 13,773 shares during the last quarter. Toronto Dominion Bank purchased a new position in shares of Caris Life Sciences in the third quarter worth $602,000. Finally, Integral Health Asset Management LLC acquired a new stake in shares of Caris Life Sciences during the third quarter worth $3,063,000.

Caris Life Sciences Company Profile

(Get Free Report)

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.

Recommended Stories

Analyst Recommendations for Caris Life Sciences (NASDAQ:CAI)

Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.